Update shared on25 Sep 2025
Fair value Increased 1.12%Driven by a modest uptick in consensus revenue growth forecasts and a slight increase in the projected future P/E, Ipsen’s analyst price target has inched up from €127.00 to €128.43.
What's in the News
- Ipsen received Japanese regulatory approval for Bylvay (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), with commercialization managed by Ipsen in Japan.
- Health Canada approved Bylvay (odevixibat) for cholestatic pruritus in Alagille Syndrome (ALGS) patients 12 months and older, supported by positive Phase III ASSERT study outcomes.
- Ipsen raised 2025 sales growth guidance to above 7% at CER, but expects a 2% adverse currency impact on total sales.
- Ipsen, in partnership with Exelixis, secured European Commission approval for CABOMETYX (cabozantinib) to treat unresectable or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in adults with prior systemic therapy, based on positive Phase III trial data.
Valuation Changes
Summary of Valuation Changes for Ipsen
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from €127.00 to €128.43.
- The Consensus Revenue Growth forecasts for Ipsen has risen slightly from 4.6% per annum to 4.7% per annum.
- The Future P/E for Ipsen has risen slightly from 15.28x to 15.60x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.